Ovid joins the re­struc­tur­ing move­ment, lay­ing off staff as Je­re­my Lev­in's crew re­fo­cus­es on epilep­sy

Af­ter tak­ing in­vestors for a roller coast­er ride over sev­er­al years filled with set­backs and re­struc­tur­ing, Ovid CEO Je­re­my Levin is re­tool­ing for an in­def­i­nite bout of cold sen­ti­ment to­ward biotech on Wall Street.

Levin in­clud­ed news that Ovid is chop­ping 20% of its work­force, with­out of­fer­ing num­bers — though the com­pa­ny spot­light­ed 57 staffers on the pay­roll at the end of 2021. That move will ex­tend the cash run­way “past 2024.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER